Eventide Asset Management’s Immunovant IMVT Stock Holding History

Eventide Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,390,000	Closed	-$21.6M	–	149
2023 Q1	$21.6M	Sell	1,390,000 -2,303,720	-62%	-$40M	0.4%	77
2022 Q4	$65.6M	Sell	3,693,720 -1,678,792	-31%	-$21.1M	1.29%	26
2022 Q3	$30M	Hold	5,372,512	–	–	0.59%	54
2022 Q2	$21M	Hold	5,372,512	–	–	0.45%	67
2022 Q1	$29.6M	Buy	5,372,512 +422,512	+9%	+$2.63M	0.46%	64
2021 Q4	$42.2M	Hold	4,950,000	–	–	0.54%	65
2021 Q3	$43M	Buy	4,950,000 +1,579,006	+47%	+$14.2M	0.57%	58
2021 Q2	$35.6M	Buy	3,370,994 +897,994	+36%	+$12.5M	0.48%	64
2021 Q1	$39.7M	Buy	2,473,000 +1,541,000	+165%	+$40.6M	0.59%	61
2020 Q4	$43M	Hold	932,000	–	–	0.66%	56
2020 Q3	$32.8M	Buy	932,000 +306,050	+49%	+$9.2M	0.64%	56
2020 Q2	$15.2M	Buy	+625,950	New	+$13.4M	0.33%	79

Other funds holding IMVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Eventide Asset Management's IMVT Position: Q2 2023 in Review

Eventide Asset Management sold out of Immunovant (IMVT) in Q2 2023, closing a stake of 1,390,000 shares — an estimated $21.6M sold.

Eventide Asset Management first reported a position in IMVT in Q2 2020 and held it in 12 quarters. The position peaked at $65.6M in Q4 2022. 147 funds tracked by Wall St. Rank hold IMVT as of Q2 2023.

Eventide Asset Management reported no remaining Immunovant position as of Q2 2023 after selling out during the quarter.
Eventide Asset Management sold 1,390,000 Immunovant shares in Q2 2023, an estimated $21.6M.
Eventide Asset Management first reported a position in Immunovant in Q2 2020 and held it in 12 quarters.
Eventide Asset Management's Immunovant position peaked at $65.6M in Q4 2022.
147 funds tracked by Wall St. Rank held Immunovant as of Q2 2023.

Based on Eventide Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.